Fullgoal CSI Medicine 50 ETF(515950) rises 1.43%, with a scale increase of 8.5051 million yuan over the past week

NewTimeSpace (newtimespace.com) News, as of 13:48 on July 14, 2026, Fullgoal Pharmaceutical 50 ETF (515950) rose 1.43%, with the latest price at 0.92 yuan. Over a longer time frame, as of July 13, 2026, the ETF accumulated a gain of 2.82% over the past two weeks, ranking 1/2 among comparable funds.

In terms of liquidity, Fullgoal Pharmaceutical 50 ETF recorded an intraday turnover rate of 3.25% and a trading volume of 18.0755 million yuan. Over a longer time frame, as of July 13, the ETF's average daily trading volume over the past year reached 16.6464 million yuan.

In terms of scale, Fullgoal Pharmaceutical 50 ETF saw a significant increase of 8.5051 million yuan in scale over the past week, with the new scale increase ranking 1/2 among comparable funds. (Data source: Wind)

In terms of shares, Fullgoal Pharmaceutical 50 ETF experienced a significant increase of 45.00 million units in share count over the past three months, with the new share increase ranking 1/2 among comparable funds. (Data source: Wind)

As of July 13, the net value of Fullgoal Pharmaceutical 50 ETF rose by 16.31% over the past two years. From the perspective of return capability, as of July 13, 2026, since its inception, the ETF achieved a highest single-month return of 23.73%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 61.70%, a ratio of up months to down months of 38/37, and an average return of 5.54% in up months. As of July 13, 2026, the ETF's annualized excess return over its benchmark for the past three months was 9.99%, ranking 1/2 among comparable funds.

In terms of drawdown, as of July 13, 2026, Fullgoal Pharmaceutical 50 ETF recorded a drawdown of 0.13% relative to its benchmark since the beginning of the year, the smallest drawdown among comparable funds.

In terms of fees, Fullgoal Pharmaceutical 50 ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of July 13, 2026, the three-year tracking error of Fullgoal Pharmaceutical 50 ETF was 0.038%, achieving the highest tracking accuracy among comparable funds.

It is worth noting that the valuation of the CSI Pharmaceutical 50 Index, which the fund tracks, is at a historical low. The latest price-to-book (PB) ratio is 3.84x, which is lower than over 86.13% of the time in the past five years, highlighting attractive valuation.

Fullgoal Pharmaceutical 50 ETF closely tracks the CSI Pharmaceutical 50 Index. The CSI Pharmaceutical 50 Index selects 50 leading listed company securities that are large in scale and have good operational quality from the healthcare industry as index constituents, in order to reflect the overall performance of leading listed company securities in the pharmaceutical industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.